Lesabelimab

N/A

Report date: 2025/10/09 10:04:56

Base Information

Drug NameLesabelimab
Drug Alias Name重组全人源抗PD-L1抗体（桂林三金）BC-003ADG-104
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsUrinary Bladder NeoplasmsPenile NeoplasmsCarcinoma, Renal Cell +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesGuilin Sanjin Pharmaceutical Co LtdAdagene (Suzhou) LtdDragonboat Biopharmaceutical +[4] 
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBaifan Biotechnology (Shanghai) Co LtdAdagene (Suzhou) LtdDragonboat Biopharmaceutical +[4] 
Inactive CompaniesN/A
Active IndicationsUrinary Bladder NeoplasmsPenile NeoplasmsCarcinoma, Renal Cell
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A